Mankind Pharma Ltd - Stock Valuation and Financial Performance

BSE: 543904 | NSE: MANKIND | Pharmaceuticals & Drugs | Large Cap

Mankind Pharma Share Price

2,152.45 33.00 1.56%
as on 12-Jul'24 16:01

DeciZen - make an informed investing decision on Mankind Pharma

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Semi Strong

Mankind Pharma stock performance -

mw4me loader
P/E Ratio (SA):
Market Cap:
86,204.7 Cr.
52-wk low:
52-wk high:

Is Mankind Pharma Ltd an attractive stock to invest in?

1. Is Mankind Pharma Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Mankind Pharma Ltd is a good quality company.

2. Is Mankind Pharma Ltd undervalued or overvalued?

The key valuation ratios of Mankind Pharma Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Mankind Pharma Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Mankind Pharma Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Mankind Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Mankind Pharma Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 24.9%21.5%21.7%20.7%22.2%15.8%27.4%25.6%23.4%16.7%-
Value Creation

Growth Parameters

Growth Parameters Colour Code Guide

Sales 2,2892,6823,1503,4953,9183,8294,7945,5237,4868,1279,265
Sales YoY Gr.-17.2%17.4%11%12.1%-2.3%25.2%15.2%35.5%8.6%-
Adj EPS 8.69.41112.216.312.323.526.934.430.745.5
YoY Gr.-10.1%16.5%11.2%33.4%-24.3%90.3%14.8%27.9%-10.8%-
BVPS (₹) 38.848.952.565.974.876.591.2118.2163.3194.3240.3
Adj Net
Cash Flow from Ops. 3553264825075405379609838211,799-
Debt/CF from Ops. 00000.70.400.10.80-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 15.1%15.7%19.2%8.6%
Adj EPS 15.3%13.5%9.4%-10.8%
Share Price - - - 18.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on
Equity %
Op. Profit
Mgn %
Net Profit
Mgn %
Debt to
Working Cap
Cash Conv.

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 19.23%

Sales growth is good in last 4 quarters at 14.27%

Return on Equity has declined versus last 3 years average to 20.90%

Net Profit has been subdued in last 3 years 9.39%

Latest Financials - Mankind Pharma Ltd.

Standalone Consolidated
TTM EPS (₹) 45.5 47.8
TTM Sales (₹ Cr.) 9,265 10,335
BVPS (₹.) 240.3 233.8
Reserves (₹ Cr.) 9,588 9,327
P/BV 8.95 9.20
PE 47.28 45.06
From the Market
52 Week Low / High (₹) 1680.50 / 2488.65
All Time Low / High (₹) 1240.75 / 2488.65
Market Cap (₹ Cr.) 86,205
Equity (₹ Cr.) 40.1
Face Value (₹) 1
Industry PE 43.9

Management X-Ray of Mankind Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Mankind Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
Operating Expenses 1,8182,1612,5042,7933,1393,1243,5504,1515,6486,429
Manufacturing Costs19325374103106147178198192
Material Costs9741,0851,1991,2961,4311,3921,5731,7822,5212,845
Employee Cost 3544325736637987859911,1671,4631,701
Other Costs 4716126797618088418391,0231,4661,691
Operating Profit 4705226457017797051,2441,3721,8381,698
Operating Profit Margin (%) 20.5%19.5%20.5%20.1%19.9%18.4%25.9%24.8%24.6%20.9%
Other Income 447376892016494155204163
Interest 212219401184828
Depreciation 2736381628386278123270
Exceptional Items 0000000000
Profit Before Tax 4865586817729336911,2651,4401,8711,563
Tax 141155207240247177307356482315
Profit After Tax 3444044755326865149581,0841,3891,248
PAT Margin (%) 15.0%15.0%15.1%15.2%17.5%13.4%20.0%19.6%18.6%15.4%
Adjusted EPS (₹)8.610.111.913.317.112.823.927.134.731.2
Dividend Payout Ratio (%)0%0%63%0%25%35%13%0%0%0%

Balance Sheet

(All Figures are in Crores.)

Equity and Liabilities

Shareholders Fund 1,5561,9592,1022,6392,9973,0653,6514,7346,5407,784
Share Capital 20202020404040404040
Reserves 1,5351,9392,0822,6192,9573,0253,6114,6946,5007,744
Minority Interest0000000000
Long Term Debt0000000000
Short Term Debt00003601900956840
Trade Payables176284326368452387487594921802
Others Liabilities 4506799165200209371444793785
Total Liabilities 2,1812,3092,5283,1724,0093,8514,5105,8678,9399,371

Fixed Assets

Gross Block2863412795336018831,1111,2223,2873,770
Accumulated Depreciation83119365178116172240366633
Net Fixed Assets2032222434815237689399822,9213,137
CWIP 214570141322211148166387495
Investments 7999447689861,4021,6981,7842,3972,5263,102
Trade Receivables132169157137243139419369471493
Cash Equivalents 1004169928172198477139155
Others Assets5894908108129704814896501,229957
Total Assets 2,1812,3092,5283,1724,0093,8514,5105,8678,9399,371

Cash Flow

(All Figures are in Crores.)
Cash Flow From Operating Activity 3553264825075405379609838211,799
PBT 4865586817729336911,2651,4401,8711,563
Adjustment -165-6-8-703213797-4227
Changes in Working Capital 17-4513-29-7359-168-156-586294
Tax Paid -132-153-206-226-250-246-274-397-460-285
Cash Flow From Investing Activity -358-382-103-513-516-306-396-1,127-1,360-1,041
Capex -400-287-64-280-231-165-164-192-2,181-580
Net Investments 00108-3218588-165-958680-506
Others 42-95-146-202-471-229-672314145
Cash Flow From Financing Activity -1-1-363-18-240-55989579-710
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid -1-1-1-1-16-41-4-5-7-26
Dividend Paid 00-3000-300-24-302000
Others 00-610324-175-25394586-684
Net Cash Flow -5-5717-831-95-554048
ROE (%)24.8822.9723.3822.4324.3516.9628.5325.8624.6517.43
ROCE (%)35.2231.8433.6532.6531.7522.1136.9534.1631.8421.2
Asset Turnover Ratio1.161.21.311.
PAT to CFO Conversion(x)1.030.811.010.950.791.0410.910.591.44
Working Capital Days
Receivable Days19201915181820252021
Inventory Days52504748464437434950
Payable Days61779398105110101111110111

Mankind Pharma Ltd Stock News

Mankind Pharma Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Mankind Pharma on 12-Jul-2024 16:01 is ₹2,152.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Jul-2024 16:01 the market cap of Mankind Pharma stood at ₹86,204.7.
The latest P/E ratio of Mankind Pharma as of 12-Jul-2024 16:01 is 47.28.
The latest P/B ratio of Mankind Pharma as of 12-Jul-2024 16:01 is 8.95.
The 52-week high of Mankind Pharma is ₹2,488.7 and the 52-week low is ₹1,680.5.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Mankind Pharma is ₹9,265 ( Cr.) .

About Mankind Pharma Ltd

Mankind Pharma was incorporated on July 3, 1991 as a private limited company under the Companies Act, 1956, with the name ‘Mankind Pharma Private Limited’, pursuant to a certificate of incorporation granted by the Registrar of Companies, Delhi and Haryana, at New Delhi (RoC). Pursuant to the conversion of the company to a public limited company and as approved by its shareholders pursuant to a special resolution dated July 14, 2005 the name of the company was changed to ‘Mankind Pharma Limited’ and the RoC issued a fresh certificate of incorporation on April 13, 2006.

The company is India’s fourth largest pharmaceutical company in terms of domestic sales and third largest in terms of sales volume for MAT December 2022 (Source: IQVIA Dataset, IQVIA TSA MAT December 2022 Dataset for India (For FY20-22)).It is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has primarily grown organically and are the youngest company among the five largest pharmaceutical companies in India, in terms of Domestic Sales in 2022 (Source: IQVIA Dataset, Annual filings / company data). It operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices, and has an established track record of building and scaling brands in-house. It has created many brands in its pharmaceutical business.
It is present in several acute and chronic therapeutic areas in India, including anti- infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals /nutrients and respiratory. It entered the consumer healthcare industry in 2007 and has since established several differentiated brands in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories.

Business area of the company

The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.

Therapeutic Area

  • Anti-infectives
  • Cardiovascular
  • Gastrointestinal
  • Vitamins/minerals/nutrients
  • Respiratory
  • Anti-diabetic
  • Dermatology
  • Gynaecology
  • Pain/analgesics
  • Neuro/CNS

Brands of the company

  • Nurokind
  • Telmikind
  • Manforce
  • Unwanted
  • Moxikind
  • Gudcef
  • Glimestar
  • Amlokind 
  • Asthakind
  • Dydroboon 
  • Prega News
  • Candiforce
  • Codistar
  • Mahacef
  • Cefakind 
  • Zenflox
  • Monticope
  • Vomikind
  • Caldikind
  • Dynaglipt

Awards, accreditations or recognition

  • 2007: Emerging Company of the year award at the Pharma Excellence Awards 2007.
  • 2011: Amity HR Excellence Award for Performance Management at the 8th Global HR Summit 2011.
  • 2017: Award for Best Design in Healthcare at Healthcare Leadership Awards 2017.
  • 2018: Best Condom Brand of the Year award at Sex Brand Awards.
  • 2018: Pharma OTC company of the year award at Pharma Excellence Awards 2018.
  • 2021: Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for manufacturing.
  • 2021: Silver Award for Good Health Brand at IHW Awards 2021.
  • 2022: E4m Pride of India - The Best of Bharat Awards 2022 by exchange4media.
  • 2022: Award for Branding and Marketing Excellence for the Strategic Initiative to Introduce DMF Quality Drugs in India at National Awards for Leadership & Excellence 2022.
  • 2022: EHS Best Practices award at Greentech International EHS Award 2023.
  • 2022: Docflix won the Digital Jalebi (DJ Interactive Solutions) award at the Maddies 2022.
  • 2022: Best Energy Efficient Case Study (SME Category) at CII National Energy Efficiency Circle Competition by Confederation of Indian Industry.
  • 2022: Short film, she can carry both by Prega News won 1st prize at Council for Fair Business Practices Consumer Film Festival.

History and milestones

  • 2004: Entered the chronic pharmaceutical segment with the launch of ‘Amlokind’ tablets and ‘Glimestar’ tablets amongst others.
  • 2005: Set up its first manufacturing facility at Paonta Sahib, Himachal Pradesh.
  • 2005: Entered the ophthalmic pharmaceutical segment with the launch of ‘Lubistar Eye Drops’ and ‘Tobastar Eye Drops’ amongst others.
  • 2007: Entered the consumer healthcare segment with the launch of ‘Manforce’ brand. 2007: Entered the animal healthcare segment with launch of ‘Bandykind’ and ‘Ceftiforce’ amongst others.
  • 2007: Raised Rs 72 crore from Monet Limited.
  • 2009: Set up its manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh.
  • 2010: Launched ‘Preganews’ brand in the consumer healthcare segment.
  • 2012: Setup its first R&D centre at IMT Manesar, Haryana.
  • 2014: Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror, Rajasthan).
  • 2014: Set up its manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh
  • 2015: Incorporated its Subsidiary, Lifestar Pharma LLC in the US.
  • 2015: Incorporated its Subsidiary, Mankind Pharma Pte. Limited in Singapore.
  • 2017: Set up its manufacturing facility in Sikkim.
  • 2018: Its manufacturing facility at Paonta Sahib, Himachal Pradesh was inspected by the USFDA for the first time.
  • 2019: Entered the female infertility segment with the launch of ‘Dydroboon’ tablets.
  • 2020: Incorporated its Subsidiary, Lifestar Pharmaceuticals Private Limited in Nepal.
  • 2020: Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of ‘Cilaheart’ tablets and ‘Statpure’ tablets.
  • 2020: Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of ‘Zukanorm’ tablets.
  • 2021: Incorporated its Subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE.
  • 2021: Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of ‘Mlife’ tablets.
  • 2021: Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of ‘Trugaba-NT’ tablets and ‘Prebris-MNT’ tablets.
  • 2022: Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited.
  • 2022: Entered into transplant segment with the launch of ‘Pangraf Capsules’ and ‘Mycept’ tablets amongst others.
  • 2022: Entered into oncology segment with the launch of ‘Pacliall’ injection amongst others.
  • 2022: Acquired the brands ‘Daffy’ and ‘Combihale’ from Dr. Reddy’s Laboratories.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.